Novartis is reportedly planning to cease approximately 20% of its drug research projects, following a strategic review, in order to focus on other priority therapeutic areas.
Zika virus (ZIKV) spread rapidly worldwide since its outbreak in May 2015 and was listed as a “public health emergency of international concern” by WHO.